Business

Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for First-line HER2-positive Recurrent or Metastatic Breast Cancer

Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for First-line HER2-positive Recurrent or Metastatic Breast Cancer

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AMay 12, 20265/news/announcement-on-voluntary-disclosure-of-completion-of-first-subject-enrollment-in-the-phase-iii-clinical-trial-of-t-bren-for-injection-her2-adc-for-first-line-her2-positive-recurrent-or-metastatic-breast-cancer
Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for First-line HER2-positive Recurrent or Metastatic Breast Cancer

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for First-line HER2-positive Recurrent or Metastatic Breast Cancer The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A